tetano
Editor, Senior Moderator
PLoS One
. 2021 Apr 21;16(4):e0249481.
doi: 10.1371/journal.pone.0249481. eCollection 2021.
The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis
Junning Wang[SUP] 1 [/SUP], Weixia Yang[SUP] 2 [/SUP], Puwen Chen[SUP] 3 [/SUP], Jianbin Guo[SUP] 4 [/SUP], Rui Liu[SUP] 4 [/SUP], Pengfei Wen[SUP] 4 [/SUP], Kun Li[SUP] 4 [/SUP], Yao Lu[SUP] 4 [/SUP], Tao Ma[SUP] 4 [/SUP], Xiaoli Li[SUP] 1 [/SUP], Siqing Qin[SUP] 4 [/SUP], Yumin Zhang[SUP] 4 [/SUP], Yakang Wang[SUP] 4 [/SUP]
Affiliations
Abstract
Objectives: Coronavirus disease 2019 (COVID-19) remains a global challenge. Corticosteroids constitute a group of anti-inflammatory and immunosuppressive drugs that are widely used in the treatment of COVID-19. Comprehensive reviews investigating the comparative proportion and efficacy of corticosteroid use are scarce. Therefore, we conducted a systematic review and meta-analysis of clinical trials to evaluate the proportion and efficacy of corticosteroid use for the treatment of COVID-19.
Methods: We conducted a comprehensive literature review and meta-analysis of research articles, including observational studies and clinical trials, by searching the PubMed, EMBASE, Cochrane Controlled Trials Registry, and China Academic Journal Network Publishing databases. Patients treated between December 1, 2019, and January 1, 2021, were included. The outcome measures were the proportion of patients treated with corticosteroids, viral clearance and mortality. The effect size with the associated 95% confidence interval is reported as the weighted mean difference for continuous outcomes and the odds ratio for dichotomous outcomes.
Results: Fifty-two trials involving 15710 patients were included. The meta-analysis demonstrated that the proportion of COVID-19 patients who received corticosteroids was significantly lower than that of patients who did not receive corticosteroids (35.19% vs. 64.49%). In addition, our meta-analysis demonstrated no significant difference in the proportions of severe and nonsevere cases treated with corticosteroids (27.91% vs. 20.91%). We also performed subgroup analyses stratified by whether patients stayed in the intensive care unit (ICU) and found that the proportion of patients who received corticosteroids was significantly higher among those who stayed in the ICU than among those who did not. The results of our meta-analysis indicate that corticosteroid treatment significantly delayed the viral clearance time. Finally, our meta-analysis demonstrated no significant difference in the use of corticosteroids for COVID-19 between patients who died and those who survived. This result indicates that mortality is not correlated with corticosteroid therapy.
Conclusion: The proportion of COVID-19 patients who received corticosteroids was significantly lower than that of patients who did not receive corticosteroids. Corticosteroid use in subjects with severe acute respiratory syndrome coronavirus 2 infections delayed viral clearance and did not convincingly improve survival; therefore, corticosteroids should be used with extreme caution in the treatment of COVID-19.
. 2021 Apr 21;16(4):e0249481.
doi: 10.1371/journal.pone.0249481. eCollection 2021.
The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis
Junning Wang[SUP] 1 [/SUP], Weixia Yang[SUP] 2 [/SUP], Puwen Chen[SUP] 3 [/SUP], Jianbin Guo[SUP] 4 [/SUP], Rui Liu[SUP] 4 [/SUP], Pengfei Wen[SUP] 4 [/SUP], Kun Li[SUP] 4 [/SUP], Yao Lu[SUP] 4 [/SUP], Tao Ma[SUP] 4 [/SUP], Xiaoli Li[SUP] 1 [/SUP], Siqing Qin[SUP] 4 [/SUP], Yumin Zhang[SUP] 4 [/SUP], Yakang Wang[SUP] 4 [/SUP]
Affiliations
- PMID: 33882090
- DOI: 10.1371/journal.pone.0249481
Abstract
Objectives: Coronavirus disease 2019 (COVID-19) remains a global challenge. Corticosteroids constitute a group of anti-inflammatory and immunosuppressive drugs that are widely used in the treatment of COVID-19. Comprehensive reviews investigating the comparative proportion and efficacy of corticosteroid use are scarce. Therefore, we conducted a systematic review and meta-analysis of clinical trials to evaluate the proportion and efficacy of corticosteroid use for the treatment of COVID-19.
Methods: We conducted a comprehensive literature review and meta-analysis of research articles, including observational studies and clinical trials, by searching the PubMed, EMBASE, Cochrane Controlled Trials Registry, and China Academic Journal Network Publishing databases. Patients treated between December 1, 2019, and January 1, 2021, were included. The outcome measures were the proportion of patients treated with corticosteroids, viral clearance and mortality. The effect size with the associated 95% confidence interval is reported as the weighted mean difference for continuous outcomes and the odds ratio for dichotomous outcomes.
Results: Fifty-two trials involving 15710 patients were included. The meta-analysis demonstrated that the proportion of COVID-19 patients who received corticosteroids was significantly lower than that of patients who did not receive corticosteroids (35.19% vs. 64.49%). In addition, our meta-analysis demonstrated no significant difference in the proportions of severe and nonsevere cases treated with corticosteroids (27.91% vs. 20.91%). We also performed subgroup analyses stratified by whether patients stayed in the intensive care unit (ICU) and found that the proportion of patients who received corticosteroids was significantly higher among those who stayed in the ICU than among those who did not. The results of our meta-analysis indicate that corticosteroid treatment significantly delayed the viral clearance time. Finally, our meta-analysis demonstrated no significant difference in the use of corticosteroids for COVID-19 between patients who died and those who survived. This result indicates that mortality is not correlated with corticosteroid therapy.
Conclusion: The proportion of COVID-19 patients who received corticosteroids was significantly lower than that of patients who did not receive corticosteroids. Corticosteroid use in subjects with severe acute respiratory syndrome coronavirus 2 infections delayed viral clearance and did not convincingly improve survival; therefore, corticosteroids should be used with extreme caution in the treatment of COVID-19.